Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07020195

QFR-Based Functional SYNTAX Score System in Optimizing Revascularization Strategy for Multivessel Disease

The revascularization treatment of multi vessel coronary artery disease (MVD) has always been a complex and important field in the treatment of coronary heart disease. The relative benefits of PCI and CABG vascular reconstruction strategies have always been a controversial topic in the field of MVD treatment. At present, SYNTAX score is the most commonly used imaging scoring system in clinical practice for quantitatively evaluating the complexity of coronary artery MVD, preliminary selection of revascularization strategies, and risk stratification. However, the SYNTAX score is entirely based on anatomical information of the lesion, and the assessment of the degree of coronary artery ischemia caused by the lesion is not accurate enough. Relying solely on anatomical structures for scoring may overestimate the harm of non ischemic lesions. The functional SYNTAX score (FSS) combines functional assessment of coronary artery lesions with anatomical structure scoring, only including lesions with hemodynamic significance, effectively optimizing the traditional SYNTAX scoring system. Compared with traditional SYNTAX scoring, FSS can reduce the number of high-risk patients, objectively evaluate the functional significance of lesions, and guide PCI treatment, significantly improving clinical prognosis.

Quantitative flow ratio (QFR) is a novel method for evaluating the functional significance of coronary artery stenosis. However, it is currently unclear whether FSS based on QFR can achieve objective and accurate risk stratification, guide the selection of revascularization strategies, and improve the long-term prognosis of patients with coronary artery MVD. Higher quality prospective clinical trials need to be designed for verification.

Therefore, this study will use a functional SYNTAX scoring system based on QFR (QFR-FSS) to conduct a prospective, multicenter, randomized controlled clinical trial to evaluate the guiding value of QFR-FSS in selecting revascularization strategies for patients with coronary artery MVD and its impact on long-term cardiovascular prognosis.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old;
  • Diagnosed as MVD patient by coronary angiography (≥ 50% stenosis in ≥ 2 major vessels);
  • Plan to undergo PCI or CABG treatment, and ensure that the contrast images meet the imaging quality requirements for QFR analysis;
  • Voluntarily sign the informed consent form, be able to participate in randomization and cooperate in completing all follow-up visits.

Exclusion criteria

  • Acute myocardial infarction requires emergency PCI;
  • Severe left ventricular dysfunction (LVEF<30%) or cardiogenic shock;
  • The quality of coronary angiography images is poor, such as vascular overlap, respiratory artifacts, projection angles less than 25 °, or frame rates less than 15 frames per second;
  • Failure of QFR analysis due to severe calcified lesions (determined by the central laboratory);
  • eGFR<30 mL/min/1.73m ² or contrast agent allergy;
  • Patients using intravenous pressors, intra aortic balloon counterpulsation, or other mechanical circulatory support devices;
  • Patients undergoing tracheal intubation treatment;
  • Patients who have received thrombolytic therapy before admission;
  • Pregnant women;
  • Expected survival time<1 year due to non cardiac reasons;
  • Patients who are not expected to receive antiplatelet therapy for at least 6 months;
  • Patients who have received CABG treatment in the past or plan to receive CABG treatment;
  • Patients who plan to undergo any surgical procedure within 6 months;
  • There are other conditions that may interfere with follow-up, such as dementia, drug abuse including drug use and drug dependence for other reasons.

Treatment and study plan

Traditional SYNTAX scoring

Procedure

Using traditional SYNTAX scoring to guide the selection of revascularization strategies

QFR-Based Functional SYNTAX Score System

Procedure

Using QFR-Based Functional SYNTAX Score System to guide the selection of revascularization strategies

Primary outcomes

  1. The incidence of major adverse cardiovascular events (MACE)

    Time frame: 2 years

    The incidence of major adverse cardiovascular events (MACE) 2 years after PCI or CABG surgery, defined as the composite endpoint of all-cause mortality, myocardial infarction, and ischemia driven revascularization.

Secondary outcomes

  1. Composite endpoint of cardiogenic death and myocardial infarction

    Time frame: 2 years

    Composite endpoint of cardiogenic death and myocardial infarction

  2. Disease success rate

    Time frame: 2 years

    Disease success rate: including lesion success evaluated by contrast imaging (evaluated by the central laboratory, with a visual residual stenosis degree of less than 30% and TIMI blood flow grade 3 for lesions treated with stent implantation); The residual stenosis degree of lesions treated with balloon dilation is less than 50% visually, TIMI blood flow grade 3, and the functional evaluation of lesions is successful (evaluated by the central laboratory, QFR ≥ 0.80 immediately after surgery).

  3. Clinical success rate

    Time frame: 2 years

    Clinical success rate: On the basis of successful imaging lesions at 30 days, 1 month, 6 months, 1 year, and 2 years after surgery, the incidence of MACE within the same hospitalization period (up to 7 days).

  4. The incidence of myocardial infarction

    Time frame: 2 years

    The incidence of myocardial infarction at 30 days, 1 month, 6 months, 1 year, and 2 years after surgery, including perioperative myocardial infarction (SCAI definition) and spontaneous myocardial infarction.

  5. The incidence of all revascularization

    Time frame: 2 years

    The incidence of all revascularization (ischemia driven, non ischemia driven revascularization; infarct related artery, non infarct related artery revascularization, culprit and non culprit lesion revascularization) at 30 days, 1 month, 6 months, 1 year, and 2 years after surgery.

  6. The incidence of confirmed and possible stent thrombosis

    Time frame: 2 year

    The incidence of confirmed and possible stent thrombosis (ARC-2 definition) at 30 days, 1 month, 6 months, 1 year, and 2 years after surgery (including stent thrombosis within the time range of acute, subacute, late, and late onset).

  7. Postoperative quality of life scores

    Time frame: 2 year

    Postoperative quality of life scores at 2 years (EQ-5D Scale).

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital of Harbin Medical University

Other

Registry information

Official study title

QFR-Based Functional SYNTAX Score System in Optimizing Revascularization Strategy for Multivessel Disease: A Prospective Multicenter Randomized Controlled Trial

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jun 13, 2025
Registry last updated
Jun 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.